A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease Journal Article

  

Authors:	Maslak, P. G.; Dao, T.; Gomez, M.; Chanel, S.; Packin, J.; Korontsvit, T.; Zakhaleva, V.; Pinilla-Ibarz, J.; Berman, E.; Scheinberg, D. A.
Article Title:	A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease
Keywords:	adult; clinical article; controlled study; aged; middle aged; clinical trial; drug efficacy; drug withdrawal; polymerase chain reaction; lymphocyte proliferation; t lymphocyte; imatinib; controlled clinical trial; granulocyte macrophage colony stimulating factor; protein binding; cytogenetics; antineoplastic activity; chronic myeloid leukemia; drug fever; immune response; amino acid sequence; molecular sequence data; gamma interferon; cancer vaccines; pilot projects; montanide isa 51; cancer immunization; cd4+ t lymphocyte; cd4-positive t-lymphocytes; drug response; patient compliance; bcr abl protein; enzyme-linked immunosorbent assay; enzyme linked immunospot assay; hla a antigen; leukemia, myelogenous, chronic, bcr-abl positive; injection site erythema; fusion proteins, bcr-abl; cell surface; peptide derivative; injection site induration; breakpoint cluster region protein; synthetic bcr abl breakpoint analog peptide; cd4 cd8 ratio
Journal Title:	Leukemia
Volume:	22
Issue:	8
ISSN:	0887-6924
Publisher:	Nature Publishing Group
Date Published:	2008-08-01
Start Page:	1613
End Page:	1616
Language:	English
DOI:	10.1038/leu.2008.7
PUBMED:	18256684
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-49449115889&partnerID=40&md5=eb794f22666cbd0abf6d0495b8bd3214
Notes:	--- - "Cited By (since 1996): 17" - "Export Date: 17 November 2011" - "CODEN: LEUKE" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/14902